Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study

Lecia V. Sequist(Harvard University), Geoffrey R. Oxnard(Foundation Medicine (United States)), Helena A. Yu(Memorial Sloan Kettering Cancer Center), Paul Frewer(AstraZeneca (United Kingdom)), Ji‐Youn Han(National Cancer Centre Japan), Lone H. Ottesen(AstraZeneca (United Kingdom)), Wu‐Chou Su(National Cheng Kung University Hospital), Myung‐Ju Ahn(Sungkyunkwan University), Remy B. Verheijen(AstraZeneca (United Kingdom)), Anders Mellemgaard(AstraZeneca (United Kingdom)), James Chih‐Hsin Yang(National Taiwan University Hospital), Byoung Chul Cho(Yonsei University), Dariusz M. Kowalski(The Maria Sklodowska-Curie National Research Institute of Oncology), Mireille Cantarini(AstraZeneca (United Kingdom)), Jong Seok Lee(Seoul National University Bundang Hospital), Xiaoling Ou(AstraZeneca (United Kingdom)), Sang-We Kim(Asan Medical Center), Sergey Orlov(St Petersburg University)
The Lancet Oncology
February 3, 2020
10.1016/s1470-2045(19)30785-5
Cited by 413

Related Papers

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Isolation of rare circulating tumour cells in cancer patients by microchip technology
|Nature|2007|3.5k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.3k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k